151 related articles for article (PubMed ID: 38551696)
1. Pro re nata anti-VEGF treatment in pachychoroid neovasculopathy compared with age-related macular degeneration based on optical coherence tomography.
Üney G; Hazırolan D; Ünlü N; Candan Ö
Int Ophthalmol; 2024 Mar; 44(1):164. PubMed ID: 38551696
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.
Matsumoto H; Hiroe T; Morimoto M; Mimura K; Ito A; Akiyama H
Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171
[TBL] [Abstract][Full Text] [Related]
3. One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy.
Kitajima Y; Maruyama-Inoue M; Ito A; Sato S; Inoue T; Yamane S; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2020 Jun; 258(6):1279-1285. PubMed ID: 32236705
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Pachychoroid Neovasculopathy.
Cho HJ; Jung SH; Cho S; Han JO; Park S; Kim JW
J Ocul Pharmacol Ther; 2019 Apr; 35(3):174-181. PubMed ID: 30807236
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy.
Yoon J; Yoon W; Na SK; Lee J; Kim CG; Kim JW; Cho HJ
Sci Rep; 2021 Jun; 11(1):12052. PubMed ID: 34103603
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of treat-and-extend versus pro re nata regimens in the treatment of Neovascular Age Macular Degeneration: A Real World Comparison.
Meira J; Carneiro J; Madeira C; Falcão M; Beato J; Correia S; Falcão-Reis F; Carneiro Â
Arch Soc Esp Oftalmol (Engl Ed); 2020 Jun; 95(6):263-270. PubMed ID: 32370878
[TBL] [Abstract][Full Text] [Related]
7. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
[TBL] [Abstract][Full Text] [Related]
8. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
[TBL] [Abstract][Full Text] [Related]
9. Pachychoroid neovasculopathy: a type-1 choroidal neovascularization belonging to the pachychoroid spectrum-pathogenesis, imaging and available treatment options.
Sartini F; Figus M; Casini G; Nardi M; Posarelli C
Int Ophthalmol; 2020 Dec; 40(12):3577-3589. PubMed ID: 32729062
[TBL] [Abstract][Full Text] [Related]
10. Vanishing pachy-choroid in pachychoroid neovasculopathy under long-term anti-vascular endothelial growth factor therapy.
Schworm B; Luft N; Keidel LF; Kreutzer TC; Herold TR; Priglinger SG; Siedlecki J
BMC Ophthalmol; 2021 Jun; 21(1):269. PubMed ID: 34193089
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes of pachychoroid neovasculopathy with photodynamic therapy and anti-vascular endothelial growth factor.
Roy R; Saurabh K; Shah D; Goel S
Indian J Ophthalmol; 2019 Oct; 67(10):1678-1683. PubMed ID: 31546507
[TBL] [Abstract][Full Text] [Related]
12. Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China.
Lai K; Huang C; Li L; Gong Y; Xu F; Zhong X; Lu L; Jin C
BMC Ophthalmol; 2020 Jun; 20(1):229. PubMed ID: 32539744
[TBL] [Abstract][Full Text] [Related]
13. Long term results of three anti-vascular endothelial growth factor agents in pachychoroid neovasculopathy.
Karasu B; Akbas YB; Kaskal M; Aykut A; Celebi ARC
Cutan Ocul Toxicol; 2022 Jun; 41(2):145-154. PubMed ID: 35579866
[TBL] [Abstract][Full Text] [Related]
14. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
Kvannli L; Krohn J
Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
[TBL] [Abstract][Full Text] [Related]
15. Changes in Choroidal Thickness After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor in Pachychoroid Neovasculopathy.
Padrón-Pérez N; Arias L; Rubio M; Lorenzo D; García-Bru P; Català-Mora J; Caminal JM
Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):1119-1124. PubMed ID: 29490349
[TBL] [Abstract][Full Text] [Related]
16. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
Hatz K; Prünte C
Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503
[TBL] [Abstract][Full Text] [Related]
17. Can objective parameters in optical coherence tomography be useful markers in the treatment and follow-up of type 1 and type 2 macular neovascularizations related to neovascular age-related macular degeneration?
Özen O; Koçak Altıntaş AG
Int Ophthalmol; 2024 Mar; 44(1):134. PubMed ID: 38483688
[TBL] [Abstract][Full Text] [Related]
18. One-year efficacy of "rescue photodynamic therapy" for patients with typical age-related macular degeneration, polypoidal choroidal vasculopathy, and pachychoroid neovasculopathy refractory to anti-vascular endothelial growth factor therapy.
Wada I; Shiose S; Ishikawa K; Kano K; Notomi S; Mori K; Akiyama M; Nakao S; Sonoda KH
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):2029-2036. PubMed ID: 35038016
[TBL] [Abstract][Full Text] [Related]
19. The association of choroidal structure and its response to anti-VEGF treatment with the short-time outcome in pachychoroid neovasculopathy.
Azuma K; Tan X; Asano S; Shimizu K; Ogawa A; Inoue T; Murata H; Asaoka R; Obata R
PLoS One; 2019; 14(2):e0212055. PubMed ID: 30763369
[TBL] [Abstract][Full Text] [Related]
20. An efficacy comparison of combination of different anti-vascular endothelial growth factors and photodynamic therapy in patients with pachychoroid neovasculopathy.
Karasu B; Celebi ARC
Int Ophthalmol; 2021 Jun; 41(6):1989-2000. PubMed ID: 33651313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
